Gloria Melissa Pacheco-Feijoó

Gloria Melissa Pacheco-Feijoó

Auto-generated profile, based on publicly available information

Gloria Melissa Pacheco-Feijoó

Department of Anesthesiology, Edgardo Rebagliati Martins National Hospital, Lima, Peru

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2023 in Indian Journal of Palliative Care
Verified
Journal Article
Open access
GPGloria Melissa Pacheco-Feijoó
Gloria Melissa Pacheco-Feijoó
Jose AmadoJose Amado
Jose Amado
RPRicardo Plancarte-Sánchez
Ricardo Plancarte-Sánchez
CVCarlos Contreras Valdivia
Carlos Contreras Valdivia
JLJose Manuel Lopez-Millan
Jose Manuel Lopez-Millan
Objectives: The management of chronic pain among patients with abdominal cancer is complex; against that, the neurolysis of the celiac plexus (CPN) is the best technique at the moment to determine the efficacy and safety in the treatment of chronic pain secondary to oncological pathology of the upper abdomen. Material and Methods: This was a systematic review of controlled clinical trials between 2000 and 2021, in the sources MEDLINE/PubMed, Cochrane, Scopus, Web of Science, and Google Scholar. Three independent evaluators analysed the results of the bibliographical research. The quality of the studies was assessed with the Jadad scale and the mean difference (95% confidence interval) and heterogeneity of the studies (I2) were calculated with Review Manager 5.3. Results: Seven hundred and forty-four publications were identified, including 13 studies in the qualitative synthesis and three studies in the quantitative synthesis. No difference was found in the decrease in pain intensity between 1 and 12 weeks after the intervention, comparing the experimental group with the control (P > 0.05). The adverse effects related to neurolysis were not serious and transitory, mentioning the most frequent adverse effects and reporting a percentage between 21% and 67% (with 17% for echoendoscopic neurolysis and 49% for percutaneous neurolysis). Conclusion: Celiac plexus neurolysis for the treatment of severe chronic pain secondary to oncological pathology in the upper hemiabdomen produces similar pain relief as conventional pharmacological analgesic treatment. It is a safe analgesic technique since the complications are mild and transitory.

18 April 2023 in Revista de la Facultad de Medicina Humana
Verified
Journal Article
Open access
PDF file
GPGloria Pacheco-Feijoó
Gloria Pacheco-Feijoó
PLPerú. Universidad Nacional Mayor de San Marcos. Lima
Perú. Universidad Nacional Mayor de San Marcos. Lima
LPLuis Podestá-Gavilano
Luis Podestá-Gavilano
KQKatherin Quevedo-Porras
Katherin Quevedo-Porras
Jose AmadoJose Amado
Jose Amado
Introduction: Quality of life is one of the main concerns for cancer patients in palliative care; however, studies on quality of life in these patients are limited. Objective: To determine the factors associated with quality of life in patients with oncological disease in palliative care. Methods: Observational, analytical study in 184 cancer patients treated in a Pain and Palliative Care Unit during 2021. The dependent variable was quality of life; independent variables were age, sex, education level, occupation, oncological diagnosis, disease duration, and stage. Crude (RP) and adjusted (aRP) prevalence ratios were calculated with a 95% confidence level. Results: The median age was 63 years, and 66.3% were female. Factors associated with quality of life were breast cancer (aRP=1.21; 95% CI: 1.07-1.36; p!<0.010), prostate cancer (aRP=1.36; 95% CI: 1.18-1.56; p!<0.010), or multiple myeloma (aRP=1.33; 95% CI: 1.15-1.53; p!<0.010), compared to other cancers such as Hodgkin's lymphoma, stomach, kidney, or pancreatic cancer; disease duration longer than 36 months (aRP=1.13; 95% CI: 1.01-1.27; p=0.040), and stage III (aRP=1.30; 95% CI: 1.19-1.42; p!<0.010) were also associated with quality of life. Conclusions: Factors associated with quality of life were having breast, prostate, or multiple myeloma cancer, compared to having another type of cancer; in addition to a disease duration longer than 36 months and stage III compared to stage I/II.